Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.

Hua CK, Ackerman ME.

Front Immunol. 2017 Nov 28;8:1655. doi: 10.3389/fimmu.2017.01655. eCollection 2017. Review.

2.

HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers.

Capucci S, Wee EG, Schiffner T, LaBranche CC, Borthwick N, Cupo A, Dodd J, Dean H, Sattentau Q, Montefiori D, Klasse PJ, Sanders RW, Moore JP, Hanke T.

PLoS One. 2017 Aug 9;12(8):e0181886. doi: 10.1371/journal.pone.0181886. eCollection 2017.

3.

Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV.

Anderson DJ, Politch JA, Zeitlin L, Hiatt A, Kadasia K, Mayer KH, Ruprecht RM, Villinger F, Whaley KJ.

AIDS. 2017 Jul 17;31(11):1505-1517. doi: 10.1097/QAD.0000000000001521.

PMID:
28463876
4.

Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge.

Pardi N, Secreto AJ, Shan X, Debonera F, Glover J, Yi Y, Muramatsu H, Ni H, Mui BL, Tam YK, Shaheen F, Collman RG, Karik├│ K, Danet-Desnoyers GA, Madden TD, Hope MJ, Weissman D.

Nat Commun. 2017 Mar 2;8:14630. doi: 10.1038/ncomms14630.

5.

Use of broadly neutralizing antibodies for HIV-1 prevention.

Pegu A, Hessell AJ, Mascola JR, Haigwood NL.

Immunol Rev. 2017 Jan;275(1):296-312. doi: 10.1111/imr.12511. Review.

6.

Patterns of HIV/SIV Prevention and Control by Passive Antibody Immunization.

Yamamoto H, Matano T.

Front Microbiol. 2016 Nov 2;7:1739. eCollection 2016. Review.

7.

Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques.

Moldt B, Le KM, Carnathan DG, Whitney JB, Schultz N, Lewis MG, Borducchi EN, Smith KM, Mackel JJ, Sweat SL, Hodges AP, Godzik A, Parren PW, Silvestri G, Barouch DH, Burton DR.

AIDS. 2016 Jun 19;30(10):1543-51. doi: 10.1097/QAD.0000000000001102.

8.

Engineering broadly neutralizing antibodies for HIV prevention and therapy.

Hua CK, Ackerman ME.

Adv Drug Deliv Rev. 2016 Aug 1;103:157-73. doi: 10.1016/j.addr.2016.01.013. Epub 2016 Jan 29. Review.

9.

HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.

Jardine JG, Ota T, Sok D, Pauthner M, Kulp DW, Kalyuzhniy O, Skog PD, Thinnes TC, Bhullar D, Briney B, Menis S, Jones M, Kubitz M, Spencer S, Adachi Y, Burton DR, Schief WR, Nemazee D.

Science. 2015 Jul 10;349(6244):156-61. doi: 10.1126/science.aac5894. Epub 2015 Jun 18.

10.

Impacts of humanized mouse models on the investigation of HIV-1 infection: illuminating the roles of viral accessory proteins in vivo.

Yamada E, Yoshikawa R, Nakano Y, Misawa N, Koyanagi Y, Sato K.

Viruses. 2015 Mar 23;7(3):1373-90. doi: 10.3390/v7031373. Review.

11.

Studies of retroviral infection in humanized mice.

Marsden MD, Zack JA.

Virology. 2015 May;479-480:297-309. doi: 10.1016/j.virol.2015.01.017. Epub 2015 Feb 11. Review.

12.

Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes.

Cardozo T, Wang S, Jiang X, Kong XP, Hioe C, Krachmarov C.

Vaccine. 2014 Sep 3;32(39):4916-24. doi: 10.1016/j.vaccine.2014.07.026. Epub 2014 Jul 18.

13.

Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice.

Stoddart CA, Galkina SA, Joshi P, Kosikova G, Long BR, Maidji E, Moreno ME, Rivera JM, Sanford UR, Sloan B, Cieplak W, Wrin T, Chan-Hui PY.

Virology. 2014 Aug;462-463:115-25. doi: 10.1016/j.virol.2014.05.036. Epub 2014 Jun 25.

14.

Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.

Trott M, Wei╬▓ S, Antoni S, Koch J, von Briesen H, Hust M, Dietrich U.

PLoS One. 2014 May 14;9(5):e97478. doi: 10.1371/journal.pone.0097478. eCollection 2014. Erratum in: PLoS One. 2014;9(8):e107089.

15.

Complement and HIV-I infection/HIV-associated neurocognitive disorders.

Liu F, Dai S, Gordon J, Qin X.

J Neurovirol. 2014 Apr;20(2):184-98. doi: 10.1007/s13365-014-0243-9. Epub 2014 Mar 18. Review.

16.

Enhanced antibody responses to an HIV-1 membrane-proximal external region antigen in mice reconstituted with cultured lymphocytes.

Holl TM, Yang G, Kuraoka M, Verkoczy L, Alam SM, Moody MA, Haynes BF, Kelsoe G.

J Immunol. 2014 Apr 1;192(7):3269-79. doi: 10.4049/jimmunol.1302829. Epub 2014 Mar 3.

17.

Genetic imprint of vaccination on simian/human immunodeficiency virus type 1 transmitted viral genomes in rhesus macaques.

Varela M, Verschoor E, Lai RP, Hughes J, Mooj P, McKinley TJ, Fitzmaurice TJ, Landskron L, Willett BJ, Frost SD, Bogers WM, Heeney JL.

PLoS One. 2013 Aug 14;8(8):e70814. doi: 10.1371/journal.pone.0070814. eCollection 2013.

18.

Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10.

Doyle-Cooper C, Hudson KE, Cooper AB, Ota T, Skog P, Dawson PE, Zwick MB, Schief WR, Burton DR, Nemazee D.

J Immunol. 2013 Sep 15;191(6):3186-3191. doi: 10.4049/jimmunol.1301285. Epub 2013 Aug 12.

19.

Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model.

Gruell H, Bournazos S, Ravetch JV, Ploss A, Nussenzweig MC, Pietzsch J.

J Virol. 2013 Aug;87(15):8535-44. doi: 10.1128/JVI.00868-13. Epub 2013 May 29.

20.

CD4 binding determinant mimicry for HIV vaccine design.

Nishiyama Y, Planque S, Hanson CV, Massey RJ, Paul S.

Front Immunol. 2012 Dec 17;3:383. doi: 10.3389/fimmu.2012.00383. eCollection 2012.

Supplemental Content

Support Center